|drug795||Closed face shield with Surgical face mask use Wiki||1.00|
There is one clinical trial.
A non-inferiority randomized controlled trial that aims to determine the effectiveness and adherence of the use of closed-face shields and surgical face masks in comparison with the use of surgical face masks for the prevention of SARS-CoV-2 infection in working adults in the city of Bogota, Colombia.
Description: The numerator will be the number of cases or the number of persons with laboratory evidence of present infection. In this case, a person with a positive result of a RT-PCR test for SARS-CoV-2 detection. The denominator will be the number of persons allocated in the determined group. Incidence of SARS-CoV-2 infection has been used as a risk measure in several studies, in which comparison groups are made. This risk measure will also allow the calculation of association measures such as RR (relative risk) in both intervention groups.Measure: COVID-19 incidence Time: 21 days of follow-up, RT-PCR test at day 21
Description: Adherence to closed face shields is defined as proper daily use of this protective element, which must be worn daily outside the home, and never touch the facial area of the protector. Face shields must be washed daily. Additionally, adherence to face masks is defined as a proper daily use which consists of wearing it covering the nose and mouth, as well as throwing it away daily. A questionnaire intended to evaluate the frequency of use and perception about the advantages of closed face shields and face mask use, as well as the barriers of their use, will be implemented in the participants at the end of the follow-up period.Measure: Adherence to closed face shields use Time: 21 days of follow-up
Description: It will be calculated as the number of participants with a positive serological test over the total of people eligible for the clinical trial at baseline.Measure: Percentage of participants with a positive serological test at baseline Time: Serological test at day 1
Description: The numerator will be the number of individuals in each group with a positive serological test at end of the study, and the denominator will be the total number of participants assigned to each group.Measure: Percentage of seroconversion in the experimental group and active control group Time: Serological test at day 21.
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports